Cover Image
市場調查報告書

全球放射性醫藥品市場趨勢

Global Radiopharmaceuticals Market Outlook 2020

出版商 KuicK Research 商品編碼 302597
出版日期 內容資訊 英文 600 Pages
商品交期: 最快1-2個工作天內
價格
Back to Top
全球放射性醫藥品市場趨勢 Global Radiopharmaceuticals Market Outlook 2020
出版日期: 2016年04月20日 內容資訊: 英文 600 Pages
簡介

全球放射性醫藥品市場佔北美地區最大的佔有率,其次是歐洲市場。由於核醫學檢驗所不可缺的Mo-99在加拿大生產,和美國進行也活躍的研究活動等,預期今後北美市場也將持續穩定成長。還有中國、印度、日本、韓國、巴西、南非等有前途有潛力的國家,以及亞太地區未來也預期將大幅成長。 這些新興國家由政府主導國內生產同位素,牽引成長。

本報告提供全球放射性醫藥品市場概要與市場趨勢,對歐洲、美國及加拿大的放射性醫藥品的指南,放射性醫藥品臨床實驗趨勢,以及參與企業的競爭環境彙整。

第1章 全球放射性醫藥品市場預測

  • 市場概要
  • 診斷及治療用放射性醫藥品
  • 臨床開發階段的放射性醫藥品

第2章 全球放射性醫藥品的市場動態

第3章 放射性醫藥品所採用的放射性元素

第4章 歐洲藥品管理局(EMA)對放射性醫藥品的指南

  • 醫藥品的物理化學、生物學,以及微生物學檢驗
  • 毒理學、藥理學檢驗
  • 臨床記錄
  • 輻射劑量檢測
  • 表示、包裝

第5章 美國食品藥物管理局(FDA)對放射性醫藥品的指南

  • 臨床適應
  • 安全性評估的一般的關懷
  • 醫療用顯影劑臨床評估

第6章 加拿大對放射性醫藥品的指南

  • 基礎研究的正子放出放射性醫藥品(PER)的使用
  • 人類介入的基礎研究的正子放出放射性醫藥品(PER)的使用
  • 現有的藥物及產品的穩定性檢驗
  • 正子放出放射性醫藥品(PER)相關GMP

第7章 各企業,適應,Phase的全球放射性醫藥品臨床實驗趨勢

第8章 各適應症的已上市放射性醫藥品

第9章 各適應,國家,Phase的中止、中斷的放射性醫藥品簡介

  • 沒有開發報告
  • 中止
  • 從市場撤退
  • 停止中

第10章 競爭環境

  • Avid Radiopharmaceuticals
  • Actinium Pharmaceuticals
  • AREVA Med
  • Bayer HealthCare Pharmaceuticals
  • Cardinal Health
  • Immunomedics
  • Lantheus Medical Imaging
  • Merck
  • Navidea
  • Nordion
  • Lantheus Medical Imaging
  • GE Healthcare
  • Ion Beam Applications
  • PETNET Solutions(Siemens Healthcare Global)

圖表

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄

Radioisotopes are radioactive isotopes having an unstable balance of atomic nucleus. Radioisotopes are produced either by using nuclear research reactor or by using cyclotron. These isotopes emit energy in the form of alpha, beta or gamma when changed to a stable nature. The gamma rays, thus emitted are used in Nuclear medicine, specifically in medical diagnostics. In this field, the radiation is used to provide diagnostic information about a human body's functioning. Radiotherapy is also used to treat some life-threatening diseases like cancer. Also, it has been observed that the increasing use of radioisotopes is one of the major reasons for a fall in deaths caused by cancer across the globe. It is because of this feature that the demand for radioisotopes or otherwise called radiopharmaceuticals is increasing significantly.

The global radiopharmaceuticals market is dominated by the North American region followed by the European region. Owing to the production of Mo-99 by the Canada and continuous research activities in different clinical institutes in USA such as National Cancer Institute, the North American market is headed for a strong growth in the future. Other markets in the Asia-Pacific region are also expected to show a significant growth in the future, with China, India, Japan, South Korea, Brazil, and South Africa being the most promising and potential regions. The major driver of growth in these countries is the domestic production of isotopes by reactors coupled with supportive government initiatives.

The radiopharmaceuticals market can be segmented into diagnostic & therapeutic radiopharmaceuticals. Close to 90% of the global radiopharmaceuticals market is dominated by diagnostic segment wherein SPECT accounts for major market share. The SPECT market is dominated by Tc-99m isotopes and F-18 accounts for majority of share in PET segment.

"Global Radiopharmaceuticals Market Outlook 2020" Report Highlight:

  • Global Radiopharmaceutical Market Overview
  • Global Radiopharmaceuticals Market Dynamics
  • FDA & EMA Guidelines for Radiopharmaceuticals
  • Global Radiopharmaceuticals Clinical Pipeline Insight by Company, Indication & Phase
  • Global Radiopharmaceuticals Clinical Pipeline: 133 Radiopharmaceuticals
  • Majority Radiopharmaceuticals in Preclinical Phase: 44 Radiopharmaceuticals
  • Marketed Radiopharmaceuticals: 19 Radiopharmaceuticals

Table of Contents

1. Global Radiopharmaceutical Market Overview

  • 1.1 Current Market Scenario
  • 1.2 Diagnostic & Therapeutic Radiopharmaceuticals
  • 1.3 Global Radiopharmaceticals Clinical Pipeline Overview

2. Global Radiopharmaceuticals Market Dynamics

3. Radioisotopes Used in Radiopharmaceuticals

4. EMA Guidelines for Radiopharmaceuticals

  • 4.1 Physico-Chemical, Biological or Microbiological Tests of Medicinal Products
  • 4.2 Toxicological & Pharmacological Tests
  • 4.3 Clinical Documentation
  • 4.4 Radiation Dosimetry
  • 4.5 Labelling & Packaging

5. FDA Guidelines for Radiopharmaceuticals

  • 5.1 Clinical Indication
  • 5.2 General Considerations for Safety Assessments
  • 5.3 Clinical Evaluation of Medical Imaging Agents

6. Canada Guidelines for Radiopharmaceuticals

  • 6.1 Use of Positron Emitting Radiopharmaceuticals (PERs) in Basic Research
  • 6.2 Use of Positron Emitting Radiopharmaceuticals in Basic Research involving Humans
  • 6.3 Stability Testing of Existing Drug Substances and Products
  • 6.4 Good Manufacturing Practices (GMP) for Positron Emitting Radiopharmaceuticals (PERs)

7. Global Radiopharmaceuticals Clinical Pipeline Insight by Company, Indication & Phase

  • 7.1 Unknown
  • 7.2 Research
  • 7.3 Preclinical
  • 7.4 Phase-0
  • 7.5 Phase-I
  • 7.6 Phase-I/II
  • 7.7 Phase-II
  • 7.8 Phase-II/III
  • 7.9 Phase-III
  • 7.10 Preregistration

8. Marketed Radiopharmaceuticals Clinical Insight by Indication

  • 8.1 Florbetapir F 18 (Amyvid)
  • 8.2 Iobenguane I-123 (AdreView)
  • 8.3 Ibritumomab Tiuxetan (Zevalin & Zevamab)
  • 8.4 Radium-223 Chloride (Alpharadin & Xofigo)
  • 8.5 Tc 99m Tilmanocept (Lymphoseek)
  • 8.6 Florbetaben F18 (NeuraCeq)
  • 8.7 Capromab (ProstaScint)
  • 8.8 Pentetreotide (Oktreotid & 111In)
  • 8.9 Iodine I 131 Derlotuximab Biotin (Cotara)
  • 8.10 Tc 99m Besilesomab (Scintimun)
  • 8.11 Samarium 153 lexidronam (Quadramet)
  • 8.12 Technetium Tc 99m Sulfur Colloid Injection
  • 8.13 Tc 99m Apcitide (AcuTect)
  • 8.14 DW 166HC (Milican)
  • 8.15 Tc 99m Sulesomab (LeukoScan)
  • 8.16 Satumomab (OncoScint CR/OV)
  • 8.17 Pentetreotide (OctreoScan & SomatoTher)
  • 8.18 Tc 99m ior cea1
  • 8.19 Tc 99m Nofetumomab Merpentan (VerLuma)

9. Discontinued & Suspended Radiopharmaceuticals by Indication & Phase

  • 9.1 No Development Reported
  • 9.2 Discontinued
  • 9.3 Market Withdrawal
  • 9.4 Suspended

10. Competitive Landscape

  • 10.1 Avid Radiopharmaceuticals
  • 10.2 Actinium Pharmaceuticals
  • 10.3 AREVA Med
  • 10.4 Bayer HealthCare Pharmaceuticals
  • 10.5 Cardinal Health
  • 10.6 Immunomedics
  • 10.7 Lantheus Medical Imaging
  • 10.8 Merck
  • 10.9 Navidea
  • 10.10 Nordion
  • 10.11 Lantheus Medical Imaging
  • 10.12 GE Healthcare
  • 10.13 Ion Beam Applications
  • 10.14 PETNET Solutions (Siemens Healthcare Global)

List of Figures

  • Figure 1-1: Global Radiopharmaceuticals Market (US$ Billion), 2014-2020
  • Figure 1-2: Global Radiopharmaceuticals Market by Region (%), 2014 & 2020
  • Figure 1-3: Global Radiopharmaceuticals Market by Region (US$ Billion), 2014 - 2020
  • Figure 1-4: Target Patient Base for Radiopharmaceuticals (Million), 2014-2020
  • Figure 1-5: Target Patient Base for Radiopharmaceuticals by Region (%), 2014 & 2020
  • Figure 1-6: Target Patient Base for Radiopharmaceuticals by Region (Million), 2014 - 2020
  • Figure 1-7: Global Radiopharmceutical Pipeline by Phase (%), 2016
  • Figure 1-8: Global Radiopharmceutical Pipeline by Phase (Numbers), 2016
  • Figure 1-9: Suspended & Discontinued Radiopharmceutical Pipeline (%), 2016
  • Figure 1-10: Suspended & Discontinued Radiopharmceutical Pipeline (Number), 2016
  • Figure 8-1: Lantheus Medical Imaging Product Pipeline

List of Tables

  • Table 1-1: Calcium-47 Investigation Properties as Radiopharmaceuticals Drug
  • Table 1-2: Carbon-11 Investigation Properties as Radiopharmaceuticals Drug
  • Table 1-3: Carbon-14 Investigation Properties as Radiopharmaceuticals Drug
  • Table 1-4: Chromium-51 Investigation Properties as Radiopharmaceuticals Drug
  • Table 1-5: Cobalt-57 Investigation Properties as Radiopharmaceuticals Drug
  • Table 1-6: Cobalt-58 Investigation Properties as Radiopharmaceuticals Drug
  • Table 1-7: Erbium-169 Investigation Properties as Radiopharmaceuticals Drug
  • Table 1-8: Fluorine-18 Investigation Properties as Radiopharmaceuticals Drug
  • Table 1-9: Gallium-67 Investigation Properties as Radiopharmaceuticals Drug
  • Table 1-10: Gallium-68 Investigation Properties as Radiopharmaceuticals Drug
  • Table 1-11: Hydrogen-3 Investigation Properties as Radiopharmaceuticals Drug
  • Table 1-12: Indium-111 Investigation Properties as Radiopharmaceuticals Drug
  • Table 1-13: Iodine-123 Investigation Properties as Radiopharmaceuticals Drug
  • Table 1-14: Iodine-125 Investigation Properties as Radiopharmaceuticals Drug
  • Table 1-15: Iodine-131 Diagnostic Investigation Properties as Radiopharmaceuticals Drug
  • Table 1-16: Iodine-131 Therapeutic Investigation Properties as Radiopharmaceuticals Drug
  • Table 1-17: Iron-59 Investigation Properties as Radiopharmaceuticals Drug
  • Table 1-18: Krypton-81m Investigation Properties as Radiopharmaceuticals Drug
  • Table 1-19: Nitrogen-13 Investigation Properties as Radiopharmaceuticals Drug
  • Table 1-20: Oxygen-15 Investigation Properties as Radiopharmaceuticals Drug
  • Table 1-21: Phosphorus-32 Investigation Properties as Radiopharmaceuticals Drug
  • Table 1-22: Radium-223 Investigation Properties as Radiopharmaceuticals Drug
  • Table 1-23: Rubidium-82 Investigation Properties as Radiopharmaceuticals Drug
  • Table 1-24: Samarium-153 Investigation Properties as Radiopharmaceuticals Drug
  • Table 1-25: Selenium-75 Investigation Properties as Radiopharmaceuticals Drug
  • Table 1-26: Sodium-22 Investigation Properties as Radiopharmaceuticals Drug
  • Table 1-27: Sodium-24 Investigation Properties as Radiopharmaceuticals Drug
  • Table 1-28: Strontium-89 Investigation Properties as Radiopharmaceuticals Drug
  • Table 1-29: Technetium-99m Investigation Properties as Radiopharmaceuticals Drug
  • Table 1-30: Thallium-201 Investigation Properties as Radiopharmaceuticals Drug
  • Table 1-31: Xenon-133 Investigation Properties as Radiopharmaceuticals Drug
  • Table 1-32: Yttrium-90 Investigation Properties as Radiopharmaceuticals Drug
Back to Top